Microarray evidence of glutaminyl cyclase gene expression in melanoma: Implications for tumor antigen specific immunotherapy

Journal of Translational Medicine

Volumn 4, Issue , 2006, Pages

  Gillis, John Stuart ^a  

^a ST THOMAS UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; COMPLEMENTARY DNA; GLUTAMIC ACID; GLUTAMINE; GLUTAMINYL CYCLASE; MELAN A; MELANOMA ANTIGEN 3; PYROGLUTAMIC ACID; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC CODE; HUMAN; INTERNET; MELANOMA; MICROARRAY ANALYSIS; MICROENVIRONMENT; PRINCIPAL COMPONENT ANALYSIS; PUBLICATION; RETROSPECTIVE STUDY;

EID: 33748151032     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-4-27     Document Type: Article

References (36)

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
2. Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T: Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994, 179:921-930.
3. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A 1994, 91:6458-6462.
4. Novellino L, Castelli C, Parmiani G: A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 2005, 54:187-207.
5. Boon T, Coulie PG, Eynde BJ, Bruggen PV: Human T Cell Responses against Melanoma. Annu Rev Immunol 2006, 24:175-208.
6. Slingluff CLJ, Speiser DE: Progress and controversies in developing cancer vaccines. J Transl Med 2005, 3:18.
7. Wang E, Panelli MC, Marincola FM: Understanding the response to immunotherapy in humans. Springer Semin Immunopathol 2005, 27:105-117.
8. Gabriele L, Moretti F, Pierotti MA, Marincola FM, Foa R, Belardelli F: The use of microarray technologies in clinical oncology. J Transl Med 2006, 4:8.
9. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24:227-235.
10. cDNA Microarray Data of the NCI 60 Cancer Cell Lines [http://discover.nci.nih.gov/datasetsNature2000.jsp]
11. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, Mesirov JP, Lander ES, Golub TR: Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001, 98:10787-10792.
12. Affymetrix Data of the NCI 60 Cancer Cell Lines [http://discover.nci.nih.gov/datasetsPnas2001.jsp]
13. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards II anticancer drugs at clinically achieved concentrations. Int J Cancer 2006, 118:1699-1712.
14. Crescenzi M, Giuliani A: The main biological determinants of tumor line taxonomy elucidated by a principal component analysis of microarray data. FEBS Lett 2001, 507:114-118.
15. Dien J: Progressing towards a consensus on PCA of ERPs. Clin Neurophysiol 2006.
16. Cattell RB: The scree test for the number of factors. Multivariate Behavioral Research 1966, 1:245-276.
17. Cattell RB: The scientific use of factor analysis in behavioral and life sciences. New York, Plenum; 1978.
18. Cattell RB: Factor analysis: An introduction to essentials, I The purpose and underlying models. Biometrics 1965, 21:190-215.
19. Cattell RB: Factor analysis: An introduction to essentials, II The role of factor analysis in research. Biometrics 1965, 21:405-435.
20. Mendez MA, Hodar C, Vulpe C, Gonzalez M, Cambiazo V: Discriminant analysis to evaluate clustering of gene expression data. FEBS Lett 2002, 522:24-28.
21. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM: Melanoma-restricted genes. J Transl Med 2004, 2:34.
22. Weeraratna AT: Serial analysis of gene expression (SAGE): advances, analysis and applications to pigment cell research. Pigment Cell Res 2003, 16:183-189.
23. Lurquin C, Lethe B, De Plaen E, Corbiere V, Theate I, van Baren N, Coulie PG, Boon T: Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 2005, 201:249-257.
24. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, Brasseur F, Lethe B, De Plaen E, Velu T, Boon T, Coulie PG: High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 2005, 201:241-248.
25. Hanagiri T, van Baren N, Neyns B, Boon T, Coulie PG: Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1. Cancer Immunol Immunother 2006, 55:178-184.
26. van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, Lienard D, Speiser D, Marchand M, Brichard VG, Escudier B, Negrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005, 23:9008-9021.
27. Bateman RCJ, Temple JS, Misquitta SA, Booth RE: Evidence for essential histidines in human pituitary glutaminyl cyclase. Biochemistry 2001, 40:11246-11250.
28. Schilling S, Hoffmann T, Manhart S, Hoffmann M, Demuth HU: Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett 2004, 563:191-196.
29. Beck A, Bussat MC, Klinguer-Hamour C, Goetsch L, Aubry JP, Champion T, Julien E, Haeuw JF, Bonnefoy JY, Corvaia N: Stability and CTL activity of N-terminal glutamic acid containing peptides. J Pept Res 2001, 57:528-538.
30. Thompson LW, Hogan KT, Caldwell JA, Pierce RA, Hendrickson RC, Deacon DH, Settlage RE, Brinckerhoff LH, Engelhard VH, Shabanowitz J, Hunt DF, Slingluff CLJ: Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity. J Immunother 2004, 27:177-183.
31. Pohl T, Zimmer M, Mugele K, Spiess J: Primary structure and functional expression of a glutaminyl cyclase. Proc Natl Acad Sci U S A 1991, 88:10059-10063.
32. Buchholz M, Heiser U, Schilling S, Niestroj AJ, Zunkel K, Demuth HU: The first potent inhibitors for human glutaminyl cyclase: synthesis and structure-activity relationship. J Med Chem 2006, 49:664-677.
33. Huang KF, Liu YL, Wang AH: Cloning, expression, characterization, and crystallization of a glutaminyl cyclase from human bone marrow: a single zinc metalloenzyme. Protein Expr Purif 2005, 43:65-72.
34. Blaszczyk J, Coillie EV, Proost P, Damme JV, Opdenakker G, Bujacz GD, Wang JM, Ji X: Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry 2000, 39:14075-14081.
35. Sykes PA, Watson SJ, Temple JS, Bateman RCJ: Evidence for tissue-specific forms of glutaminyl cyclase. FEBS Lett 1999, 455:159-161.
36. Dooley TP, Curto EV, Davis RL, Grammatico P, Robinson ES, Wilborn TW: DNA microarrays and likelihood ratio bioinformatic methods: discovery of human melanocyte biomarkers. Pigment Cell Res 2003, 16:245-253.